NEW YORK (Reuters) - Merck & Co posted quarterly revenue ahead of analysts' estimates yesterday, helped by strong sales of its diabetes and allergy drugs, and stuck by its goals from its merger with Schering-Plough Corp.

Merck shares rose two percent as the drugmaker reported quarterly profit that matched Wall Street expectations.

"The numbers look broadly speaking right in line," Deutsche Bank analyst Barbara Ryan said. "Everything looks good and on track."

Merck chief executive Richard Clark said the company remained firmly committed to its financial targets from the $41 billion Schering deal. Earlier this month, Pfizer Inc, which is digesting its own huge takeover of Wyeth, lowered its 2012 financial forecasts as analysts cited unexpectedly high spending.

Combined sales of Merck's diabetes treatments Januvia and Janumet jumped 43 percent in the fourth quarter to $760 million, even as the products began to face competition from a rival drug from Bristol-Myers Squibb Co and AstraZeneca Plc. The drugs' sales topped the expectations of Leerink Swann analyst Seamus Fernandez by $60 million.

Sales of its Singulair allergy pill rose 12 percent to $1.3 billion, $44 million above the estimate of Fernandez, who said Merck's overall revenue was very strong.

Combined sales of its cholesterol drugs Vytorin and Zetia, which have faced questions over safety and effectiveness, rose about six percent to $1.19 billion.